 |
In this issue
January - February
1999
The CFIDS Chronicle
AACFS
Conference
Research Presentations, Treatment Strategies and Patient Voices:
A 14-page Special
Report
Reports from the biennial conference of the American Association for Chronic Fatigue Syndrome,Cambridge,
Mass., October 1998.
Research Opens New Avenues for
Exploration
More than 90 presentations represent 27 countries.
Attention Focused on
Pediatric CFS
Specialists propose formal statement, research focusing
on the effects of this illness on children.
Poster
Presentations
Many of the 90-plus
research presentations were made as posters. They include research by
scientists from Japan, Italy, Sweden and Brazil.
Disability
a Difficult
Issue
Experts in CFS disability offer several perspectives.
Diagnosis
and
Treatment Strategies
A panel of CFS specialists discusses
laboratory tests, medications, stress management and more.
Psychiatrists Reject
Either/Or Approach
A panel of psychiatrists justify
their profession's place in treating CFS. One panel member makes a strong
statement against automatic psychiatric evaluations.
Patients Speak
Out
During
the conference, the voices of patients were heard, giving a human context to the proceedings.
Features
Q &
A on Ampligen
Hemispherx Biopharma's Medical Director, Dr. David R.
Strayer, responds to some of the most asked questions about Ampligen as the
drug begins another clinical trial.
Galantamine Begins Phase II
Trial
Shire Pharmaceutical's drug will
be tested at 12 clinics around the United States.
Clinical Trials: What
Do They Offer the Volunteer?
Thinking about joining a clinical trial? Here are some
things to consider, and what investigators and drug manufacturers have to tell
you first.
Research
News
Studies continue progress toward understanding CFIDS.
Departments
From the editor:
This issue continues our coverage of the 1998 AACFS conference.
We look forward to following promising research and continuing to explore other critical issues.
We
also offer an update on Ampligen in the form of a Q&A with Dr. David R. Strayer, Medical Director
for Hemispherx Biopharma, responding to a number of frequently asked questions about that investigational
drug. Another investigational drug, galantamine hydrobromide, manufactured by Shire Laboratories of England,
also begins clinical trials in the United States. If you are considering participating in a clinical trial,
read the article on page 9. It is full of information you should consider when making such a decision.
Plans for upcoming issues of the Chronicle
include a look at the
controversy surrounding cognitive behavior therapy and a discussion with a doctor whose approach to treating
CFIDS centers on nutrition. We ll also turn our focus to issues of living with CFIDS, with a recognition
of caregivers and contributions from a number of your fellow PWCs.
David M. Hoh, Editor
|
